论文部分内容阅读
目的：观察慢性肾功能不全患者血浆内皮素（ＥＴ）、血栓素Ｂ２（ＴＸＢ２）和６酮前列腺素Ｆ１α（６ｋｅｔｏＰＧＦ１α）含量及其临床意义。方法：使用放射免疫分析法检测１４例氮质血症及１０例尿毒症患者血浆ＥＴ、ＴＸＢ２和６ｋｅｔｏＰＧＦ１α含量，并与正常对照组比较。结果：氮质血症组血浆ＥＴ为６５．３８±１９．１８ｎｇ／Ｌ，ＴＸＢ２为１０５．８４±９６．２４ｎｇ／Ｌ，６ｋｅｔｏＰＧＦ１α为３６．１４±３０．７２ｎｇ／Ｌ；尿毒症组ＥＴ为１２６．５０±５３．５５ｎｇ／Ｌ，ＴＸＢ２为３７２．６５±２８６．２２ｎｇ／Ｌ，６ｋｅｔｏＰＧＦ１α为２３．６２±１４．５６ｎｇ／Ｌ，均明显高于正常对照组。此外，结果还显示，血液透析（血透）后患者血ＥＴ含量显著下降（６４．１２±２５．１６ｎｇ／Ｌ与１２４．２８±５１．４１ｎｇ／Ｌ）。结论：慢性肾功能不全患者血浆ＥＴ含量升高，尤以尿毒症期为显著，血透后可降低。特别是早期血透对消除尿毒症高ＥＴ血症具有重要临床意义。本资料为临床应用ＥＴ拮抗剂治疗慢性肾功能不全提供参考依据。
Objective: To observe the content of endothelin (ET), thromboxane B2 (TXB2) and 6ketoPGF1α in patients with chronic renal insufficiency and its clinical significance. Methods: The contents of plasma ET, TXB2 and 6ketoPGF1α in 14 patients with azotemia and 10 patients with uremia were measured by radioimmunoassay and compared with the normal control group. Results: In the azotemia group, plasma ET was 65.38 ± 19.18 ng / L, TXB2 was 105.84 ± 96.24 ng / L, 6ketoPGF1α was 36.14 ± 30.72 ng / L, uremia group ET was 126 .50 ± 53.55ng / L, TXB2 was 372.65 ± 286.22ng / L, and 6ketoPGF1α was 23.62 ± 14.56ng / L, which were significantly higher than that of the normal control group. In addition, the results also showed a significant decrease in ET blood levels (64.12 ± 25.16 ng / L and 124.28 ± 51.41 ng / L) in patients with hemodialysis (hemodialysis). Conclusion: Plasma ET levels are elevated in patients with chronic renal failure, especially in uremia, and may be reduced after hemodialysis. In particular, early hemodialysis on the elimination of uremic hyperaemia has important clinical significance. This data provides a reference for the clinical application of ET antagonist in the treatment of chronic renal insufficiency.